Skip to main content
Government Resource

FDA cautions about dose confusion and medication errors for antibacterial drug Zerbaxa (ceftolozane and tazobactam).

Food and Drug Administration; FDA.

Save
Print
June 3, 2015
Food and Drug Administration; FDA.

Dosing information on drug labels should be clearly articulated to prevent confusion. This announcement raises awareness of a drug strength labeling change regarding active ingredients in the antibacterial drug Zerbaxa to improve dosing accuracy.

Save
Print
Cite
Citation

Food and Drug Administration; FDA.

Related Resources From the Same Author(s)
Related Resources